|
|
 Previous Article | Table of Contents | Next Article 
bcl-2 gene expression in hematopoietic cell differentiation
MT Mariano, L Moretti, A Donelli, M Grantini, G Montagnani, AU Di Prisco, G Torelli, U Torelli and F Narni
Istituto di Clinica Medica II, Universita di Modena, Italy.
Nonrandom translocations with breakpoint at band q21 on chromosome 18 might
cause bcl-2 gene deregulation and might contribute to neoplastic
transformation in human lymphomas. As the pattern of expression of bcl- 2
in hematopoietic cells is still unclear, we have measured the level of the
corresponding messenger RNA (mRNA) in a variety of myeloid and lymphoid
cell malignancies not usually associated with the t(14;18) translocation.
Molecular genetic analysis showed that bcl-2 was rearranged in only 2 of 77
patients: one was affected by hairy cell leukemia and one by diffuse small
cleaved cell lymphoma with peripheral blood invasion. Although in rare
cases of myeloid leukemia fairly high levels can be found, the expression
of bcl-2 appears to be typical of certain lymphoid malignancies. High
levels of bcl-2 mRNA had been found, previously, in established pre-B-cell
lines. However, in fresh specimens, the peak level of bcl-2 expression
shifts to a more differentiated cell type, represented by the long-living B
lymphocytes that are found in most cases of chronic lymphocytic leukemia.
bcl-2 gene product might have a role in prolonging cell survival and, even
in the absence of translocations, might contribute to some of the biologic
features that are typical of this disorder.
Volume 80,
Issue 3,
pp. 768-775,
08/01/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. F. Santidrian, A. M. Cosialls, L. Coll-Mulet, D. Iglesias-Serret, M. de Frias, D. M. Gonzalez-Girones, C. Campas, A. Domingo, G. Pons, and J. Gil
The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells
Haematologica,
December 1, 2007;
92(12):
1631 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Renner, J. Weisz, S. Krajewski, M. Krajewska, J. C. Reed, and A. Lichtenstein
Expression of BAX in Plasma Cell Dyscrasias
Clin. Cancer Res.,
June 1, 2000;
6(6):
2371 - 2380.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. H. Kaufmann, J. E. Karp, P. A. Svingen, S. Krajewski, P. J. Burke, S. D. Gore, and J. C. Reed
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Blood,
February 1, 1998;
91(3):
991 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bellosillo, M. Dalmau, D. Colomer, and J. Gil
Involvement of CED-3/ICE Proteases in the Apoptosis of B-Chronic Lymphocytic Leukemia Cells
Blood,
May 1, 1997;
89(9):
3378 - 3384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
